Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate

Executive Summary

Firms could find themselves charged multiple US generic drug user fees if affiliates are not identified and ANDAs claimed.

You may also be interested in...



Fresenius Steps Up International Ambition Through Akorn Pursuit

German healthcare company Fresenius SE & Co. pursues a second major international deal in less than year, as new CEO confirms interest in US generics firm Akorn.

Generic Industry Hit With Avalanche Of Price Fixing Suits

As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits on behalf of third party payers.

Generic Industry Consolidation Illustrated In ANDA Holder List

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel